StockStory
Q4 Earnings Outperformers: Labcorp (NYSE:LH) And The Rest Of The Testing & Diagnostics Services Stocks
➖
AI Sentiment
Neutral
4/10
- Home
- LH
as of 03-13-2026 3:43pm EST
$263.28
+$0.37
+0.14%
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
| Founded: | 1971 | Country: | United States |
| Employees: | 70000 | City: | BURLINGTON |
| Market Cap: | 20.9B | IPO Year: | 2005 |
| Target Price: | $308.30 | AVG Volume (30 days): | 596.6K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 10.46 | EPS Growth: | 18.33 |
| 52 Week Low/High: | $209.38 - $293.72 | Next Earning Date: | N/A |
| Revenue: | $13,951,700,000 | Revenue Growth: | 7.25% |
| Revenue Growth (this year): | 8.36% | Revenue Growth (next year): | 4.73% |
| P/E Ratio: | 25.12 | Index: | |
| Free Cash Flow: | 1.2B | FCF Growth: | +10.05% |
AI-Powered LH Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 68.13%
68.13%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Laboratory Corporation of America Holdings (LH)
Schechter Adam H
Sell
President & CEO
LH Mar 3, 2026
Avg Cost/Share
$279.96
Shares
8,705
Total Value
$2,437,047.45
Owned After
80,773
SEC Form 4
van der Vaart Sandra D
Sell
EVP, Corporate Affairs
LH Feb 27, 2026
Avg Cost/Share
$284.91
Shares
547
Total Value
$155,999.54
Owned After
2,578.947
SEC Form 4
Caveney Brian J
Sell
EVP, Pres of ED, CMO & CSO
LH Feb 24, 2026
Avg Cost/Share
$286.31
Shares
1,500
Total Value
$429,457.50
Owned After
30,106.923
SEC Form 4
Wilkinson Peter J
Sell
SVP, Chief Accounting Officer
LH Feb 19, 2026
Avg Cost/Share
$277.94
Shares
666
Total Value
$185,108.04
Owned After
1,852.219
SEC Form 4
Meltzer Jonathan C
Sell
EVP, Operations
LH Feb 12, 2026
Avg Cost/Share
$290.42
Shares
87
Total Value
$25,266.54
Owned After
2,782.326
SEC Form 4
Schechter Adam H
Sell
President & CEO
LH Feb 11, 2026
Avg Cost/Share
$284.38
Shares
5,273
Total Value
$1,499,535.74
Owned After
80,773
SEC Form 4
Meltzer Jonathan C
Sell
EVP, Operations
LH Feb 10, 2026
Avg Cost/Share
$276.79
Shares
91
Total Value
$25,187.89
Owned After
2,782.326
SEC Form 4
Meltzer Jonathan C
Sell
EVP, Operations
LH Feb 9, 2026
Avg Cost/Share
$275.53
Shares
88
Total Value
$24,246.64
Owned After
2,782.326
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Schechter Adam H | LH | President & CEO | Mar 3, 2026 | Sell | $279.96 | 8,705 | $2,437,047.45 | 80,773 | |
| van der Vaart Sandra D | LH | EVP, Corporate Affairs | Feb 27, 2026 | Sell | $284.91 | 547 | $155,999.54 | 2,578.947 | |
| Caveney Brian J | LH | EVP, Pres of ED, CMO & CSO | Feb 24, 2026 | Sell | $286.31 | 1,500 | $429,457.50 | 30,106.923 | |
| Wilkinson Peter J | LH | SVP, Chief Accounting Officer | Feb 19, 2026 | Sell | $277.94 | 666 | $185,108.04 | 1,852.219 | |
| Meltzer Jonathan C | LH | EVP, Operations | Feb 12, 2026 | Sell | $290.42 | 87 | $25,266.54 | 2,782.326 | |
| Schechter Adam H | LH | President & CEO | Feb 11, 2026 | Sell | $284.38 | 5,273 | $1,499,535.74 | 80,773 | |
| Meltzer Jonathan C | LH | EVP, Operations | Feb 10, 2026 | Sell | $276.79 | 91 | $25,187.89 | 2,782.326 | |
| Meltzer Jonathan C | LH | EVP, Operations | Feb 9, 2026 | Sell | $275.53 | 88 | $24,246.64 | 2,782.326 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 17, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 17, 2026 · 100% conf.
AI Prediction SELL
1D
-0.95%
$274.03
Act: +0.76%
5D
-1.80%
$271.69
Act: +3.78%
20D
-1.24%
$273.24
Price: $276.67 Prob +5D: 0% AUC: 1.000
0000920148-26-000098
lh-202602170000920148false00009201482026-02-172026-02-17
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
February 17, 2026 (Date of earliest event reported)
LABCORP HOLDINGS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits. ExhibitExhibit Name Exhibit 99.1Press Release dated February 17, 2026 issued by Labcorp titled “Labcorp Announces 2025 Fourth Quarter and Full Year Results”
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABCORP HOLDINGS INC.
Registrant
Date: February 17, 2026By:/s/ KATHRYN W. KYLE Kathryn W. Kyle Executive Vice President, Chief Legal Officer and Corporate Secretary
2025 Q3 Q3 2025 Earnings
8-K Oct 28, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 28, 2025
0000920148-25-000093
lh-202510280000920148false00009201482025-10-282025-10-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
October 28, 2025 (Date of earliest event reported)
LABCORP HOLDINGS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits. ExhibitExhibit Name Exhibit 99.1Press Release dated October 28, 2025 issued by Labcorp titled “Labcorp Announces 2025 Third Quarter Results”
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABCORP HOLDINGS INC.
Registrant
Date: October 28, 2025By:/s/ SANDRA D. VAN DER VAART Sandra D. van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
2025 Q2 Q2 2025 Earnings
8-K Jul 24, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 24, 2025
0000920148-25-000075
lh-202507240000920148false00009201482025-07-242025-07-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
July 24, 2025 (Date of earliest event reported)
LABCORP HOLDINGS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits. ExhibitExhibit Name Exhibit 99.1Press Release dated July 24, 2025 issued by Labcorp titled “Labcorp Announces 2025 Second Quarter Results”
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABCORP HOLDINGS INC.
Registrant
Date: July 24, 2025By:/s/ SANDRA D. VAN DER VAART Sandra D. van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
2025 Q1 Q1 2025 Earnings
8-K Apr 29, 2025
2025
Q1
Q1 2025 Earnings
8-KApr 29, 2025
0000920148-25-000054
lh-202504290000920148false00009201482025-04-292025-04-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
April 29, 2025 (Date of earliest event reported)
LABCORP HOLDINGS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits. ExhibitExhibit Name Exhibit 99.1Press Release dated April 29, 2025 issued by Labcorp titled “Labcorp Announces 2025 First Quarter Results”
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABCORP HOLDINGS INC.
Registrant
Date: April 29, 2025By:/s/ SANDRA D. VAN DER VAART Sandra D. van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
2024 Q4 Q4 2024 Earnings
8-K Feb 6, 2025
2024
Q4
Q4 2024 Earnings
8-KFeb 6, 2025
0000920148-25-000021
lh-202502060000920148false00009201482025-02-062025-02-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
February 6, 2025 (Date of earliest event reported)
LABCORP HOLDINGS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits. ExhibitExhibit Name Exhibit 99.1Press Release dated February 6, 2025 issued by Labcorp titled “Labcorp Announces 2024 Fourth Quarter and Full Year Results”
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABCORP HOLDINGS INC.
Registrant
Date: February 6, 2025By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
2024 Q3 Q3 2024 Earnings
8-K Oct 24, 2024
2024
Q3
Q3 2024 Earnings
8-KOct 24, 2024
0000920148-24-000115
lh-20241024October 24, 20240000920148false00009201482024-10-242024-10-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
October 24, 2024 (Date of earliest event reported)
LABCORP HOLDINGS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated October 24, 2024 issued by Labcorp titled "Labcorp Announces 2024 Third Quarter Results"
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
October 24, 2024
2024 Q2 Q2 2024 Earnings
8-K Aug 1, 2024
2024
Q2
Q2 2024 Earnings
8-KAug 1, 2024
0000920148-24-000096
lh-20240801August 01, 20240000920148false00009201482024-08-012024-08-01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
August 01, 2024 (Date of earliest event reported)
LABCORP HOLDINGS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated August 1, 2024 issued by Labcorp titled "Labcorp Announces 2024 Second Quarter Results"
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
August 01, 2024
2024 Q1 Q1 2024 Earnings
8-K Apr 25, 2024
2024
Q1
Q1 2024 Earnings
8-KApr 25, 2024
0000920148-24-000029
lh-20240425April 25, 20240000920148false00009201482024-04-252024-04-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
April 25, 2024 (Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated April 25, 2024 issued by Labcorp titled "Labcorp Announces 2024 First Quarter Results"
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
April 25, 2024
2023 Q4 Q4 2023 Earnings
8-K Feb 15, 2024
2023
Q4
Q4 2023 Earnings
8-KFeb 15, 2024
0000920148-24-000009
lh-20240215February 15, 20240000920148FALSE00009201482024-02-152024-02-15
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
February 15, 2024 (Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135313-3757370 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock, $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated February 15, 2024 issued by Labcorp
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
February 15, 2024
2023 Q3 Q3 2023 Earnings
8-K Oct 26, 2023
2023
Q3
Q3 2023 Earnings
8-KOct 26, 2023
0000920148-23-000078
lh-20231026October 26, 20230000920148false00009201482023-10-262023-10-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
October 26, 2023 (Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated October 26, 2023 issued by Labcorp titled "Labcorp Announces 2023 Third Quarter Results"
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
October 26, 2023
2023 Q2 Q2 2023 Earnings
8-K Jul 27, 2023
2023
Q2
Q2 2023 Earnings
8-KJul 27, 2023
0000920148-23-000058
lh-20230727July 27, 20230000920148false00009201482023-07-272023-07-27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
July 27, 2023 (Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated July 27, 2023 issued by Labcorp titled "Labcorp Announces 2023 Second Quarter Results"
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
July 27, 2023
2023 Q1 Q1 2023 Earnings
8-K Apr 25, 2023
2023
Q1
Q1 2023 Earnings
8-KApr 25, 2023
0000920148-23-000023
lh-20230425April 25, 20230000920148false00009201482023-04-252023-04-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
April 25, 2023 (Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated April 25, 2023 issued by Labcorp titled "Labcorp Announces 2023 First Quarter Results"
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
April 25, 2023
2022 Q4 Q4 2022 Earnings
8-K Feb 16, 2023
2022
Q4
Q4 2022 Earnings
8-KFeb 16, 2023
0000920148-23-000012
lh-20230216February 16, 20230000920148FALSE00009201482023-02-162023-02-16
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
February 16, 2023 (Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135313-3757370 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock, $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated February 16, 2023 issued by Labcorp
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
February 16, 2023
2022 Q3 Q3 2022 Earnings
8-K Oct 27, 2022
2022
Q3
Q3 2022 Earnings
8-KOct 27, 2022
0000920148-22-000055
lh-20221027October 27, 20220000920148false00009201482022-10-272022-10-27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
October 27, 2022 (Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated October 27, 2022 issued by Labcorp titled "Labcorp Announces 2022 Third Quarter Results"
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
October 27, 2022
2022 Q2 Q2 2022 Earnings
8-K Jul 28, 2022
2022
Q2
Q2 2022 Earnings
8-KJul 28, 2022
0000920148-22-000038
lh-20220728July 28, 20220000920148false00009201482022-07-282022-07-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
July 28, 2022 (Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
On July 28, 2022, Laboratory Corporation of America Holdings (Labcorp) issued a press release reporting financial results for the three months ended June 30, 2022. A copy of Labcorp’s press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 7.01Regulation FD Disclosure
On July 28, 2022, Labcorp announced that its board of directors authorized Labcorp to pursue a spin-off of its wholly owned Clinical Development business, which includes the parts of its Drug Development segment focused on providing Phase I-IV clinical trial management, market access and technology solutions to pharmaceutical and biotechnology organizations. A copy of Labcorp’s press release is attached to this Current Report on Form 8-K as Exhibit 99.2.
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated July 28, 2022 issued by Labcorp titled "Labcorp Announces 2022 Second Quarter Results"
Exhibit 99.2Press Release dated July 28, 2022 issued by Labcorp titled "Labcorp to Spin Off Clinical Development Business"
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
July 28, 2022
2022 Q1 Q1 2022 Earnings
8-K Apr 28, 2022
2022
Q1
Q1 2022 Earnings
8-KApr 28, 2022
0000920148-22-000022
lh-20220428April 28, 20220000920148false00009201482022-04-282022-04-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
April 28, 2022 (Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated April 28, 2022 issued by Labcorp
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
April 28, 2022
2021 Q4 Q4 2021 Earnings
8-K Feb 10, 2022
2021
Q4
Q4 2021 Earnings
8-KFeb 10, 2022
0000920148-22-000011
lh-20220210February 10, 20220000920148FALSE00009201482022-02-102022-02-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
February 10, 2022 (Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135313-3757370 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock, $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated February 10, 2022 issued by Labcorp
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
February 10, 2022
2021 Q3 Q3 2021 Earnings
8-K Oct 28, 2021
2021
Q3
Q3 2021 Earnings
8-KOct 28, 2021
0000920148-21-000066
lh-20211028October 28, 20210000920148false00009201482021-10-282021-10-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
October 28, 2021 (Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated October 28, 2021 issued by Labcorp
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
October 28, 2021
2021 Q2 Q2 2021 Earnings
8-K Jul 29, 2021
2021
Q2
Q2 2021 Earnings
8-KJul 29, 2021
0000920148-21-000048
lh-20210729July 29, 20210000920148false00009201482021-07-292021-07-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
July 29, 2021 (Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated July 29, 2021 issued by Labcorp
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
July 29, 2021
2021 Q1 Q1 2021 Earnings
8-K Apr 29, 2021
2021
Q1
Q1 2021 Earnings
8-KApr 29, 2021
0000920148-21-000038
lh-20210429April 29, 20210000920148false00009201482021-04-292021-04-2900009201482020-10-272020-10-27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
April 29, 2021 (Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated April 29, 2021 issued by Labcorp
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
April 29, 2021
Latest Laboratory Corporation of America Holdings News
LH Breaking Stock News: Dive into LH Ticker-Specific Updates for Smart Investing
Compare LH vs Leading Stocks
See how LH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LH Laboratory Corporation of America Holdings - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.